Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mastermind-like protein 1 (MAML1) is a nuclear transcriptional coactivator that acts as a central integrator of the Notch signaling cascade by forming a ternary complex with the Notch intracellular domain and CSL DNA-binding protein, thereby activating target gene expression. MAML1 also modulates other major pathways, particularly Wnt/β-catenin-mediated transcription, and interacts with pivotal transcription factors such as MEF2C and p53, coordinating cellular processes including differentiation, proliferation, and apoptosis. Alterations in MAML1 activity are implicated in the development of diverse malignancies and muscle diseases, positioning it as a key node in transcriptional regulation and a potential point of therapeutic intervention.
Indirect inhibition via Notch pathway antagonists (such as γ-secretase inhibitors, which prevent the formation of the active Notch intracellular domain needed for MAML1 complex formation). Dominant-negative MAML1 constructs used experimentally block coactivation functions.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mastermind-like protein 1 (MAML1).